Leveraging Reverse Transcriptase in HIV
Meeting category
Date(s)
22 Sep 2020
Organizer

Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020

Related Enduring Materials

Enduring Materials
22 September 2020 - 18:00
18:00 CEST
Welcome Opening of Virtual Symposium
Jonathan Schapiro, MD
National Hemophilia Center, Sheba Medical Center, Israel
18:10 CEST
Historical perspective: Inhibiting the RT enzyme and curtailing the AIDS pandemic
Judith Currier, MD, MSC
University of California, Los Angeles (UCLA), United States
18:25 CEST
Mechanisms of action: NNRTI
Daniel Kuritzkes, MD
Brigham and Women's Hospital / Harvard Medical School, United States
18:40 CEST
Mechanisms of action: NRTI and NRTTI
Martin Markowitz, MD
Rockefeller University, United States
19:00 CEST
Q&A - Questions submitted online by viewers
19:30 CEST
Clinical Review: New RT inhibitors – Doravirine​ ​
Chloe Orkin, MBChB, FRCP, MD
Queen Mary University of London, United Kingdom
19:50 CEST
Clinical Review: New RT inhibitors – Islatravir
Jean-Michel Molina, MD, PhD
Saint-Louis/Lariboisière Hospitals and University of Paris, France
20:10 CEST
Toxicity of different drugs classes and their clinical implication
Laura Waters, MD, FRCP
Central & North West London NHS Foundation Trust, United Kingdom
20:25 CEST
Optimal use of NRTTI + NNRTI regimens in routine clinic practice
Anton Pozniak, MD, FRCP
Chelsea and Westminster Hospital, United Kingdom
20:45 CEST
Q&A - Questions submitted online by viewers
21:10 CEST
Conclusions Closure of Virtual Symposium
Jonathan Schapiro, MD
National Hemophilia Center, Sheba Medical Center, Israel
Overview
Welcome

Inhibition of the reverse transcriptase enzyme has played a critical role in the treatment and prevention of HIV from the earliest days of the epidemic through to the present.

​Although current antiretroviral (ARV) therapies effectively control HIV in the majority of patients, unmet needs remain, including reduced toxicity, improved dosing, more convenient delivery, and long-term prevention of resistance.  In the absence of an effective HIV vaccine and/or a cure regimen, it is imperative that ARV drug pipelines continue to pursue new and improved options.

​Important new data on next generation reverse transcriptase inhibitors (RTIs) is being presented and published at an increasingly rapid rate.  This 3-hour virtual program offers an educational opportunity for healthcare practitioners to both revisit the history of RTIs and become informed of recent developments in the field.  In particular, this program will present and discuss preclinical and clinical information regarding 3 classes of RTIs:  NRTIs, NNRTIs, and NRTTIs.

Program Director

Practical Information 

Language
The language of this meeting in English.
Disclaimer
This meeting is intended for educational purposes only and aims to offer participants the opportunity to share information. The conference secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the meeting.
Liability and Insurance
By registering for the meeting, participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Support
Support

This educational meeting has been organized by Virology Education on behalf of MSD.

This meeting has been fully funded by MSD.

Language